Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Recruiting
Phase 2
Interventional Study
Alzheimer Disease
Mild Cognitive Impairment
Dementia
Healthy Volunteers
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 120
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 200 (estimated)
- Sponsor
- Akiva Mintz · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Age ≥18 years; Ability to provide informed consent and comply with study procedures; For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.
Exclusion Criteria:
Participants who have exceeded NRC reg…
Contacts